Inhibitory effects on pulmonary metastases of low-dose consecutive administration of cisplatin on sarcoma-bearing mice.
Low-dose consecutive CDDP administrations have been reported to be effective in cancer treatment. We studied the inhibitory effects on pulmonary metastasis of bolus versus low-dose consecutive administration of CDDP chemotherapy for sarcoma-bearing mice, and evaluated the differences in responses to two types of therapy. Significant reductions (p < 0.01) in the number of pulmonary metastases were observed in the low-dose consecutive administration group compared to the control group, and in the bolus group compared to the control group. No significant difference in the number of metastases between the low-dose consecutive administration group and the bolus group was observed (p = 0.43). This study suggests that low-dose consecutive CDDP administration would be as effective as bolus CDDP administration, which is currently popular. Also, low-dose consecutive CDDP administrations may contribute to the attenuation of the adverse drug reactions expected by patients with bone and soft tissue tumors who are undergoing chemotherapy.
Takeda
Akira
A
Department of Orthopedic Surgery, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan. takeda@fmu.ac.jp
Tsuchiya
Hiroyuki
H
Tajino
Takahiro
T
Sato
Katsuhiko
K
Kikuchi
Shinichi
S
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001835:Body Weight / Q000187:drug effects; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D002945:Cisplatin